Barclays
GENB icon

Barclays’s Generate Biomedicines GENB Stock Holding History

Barclays’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.78M Buy
118,474
+1,572
+1% +$24.2K ﹤0.01% 2666
2026
Q2 		$1.97M Buy
116,902
+46,008
+65% +$627K ﹤0.01% 2346
2026
Q1 		$886K Buy
+70,894
New +$866K ﹤0.01% 2825

Other funds holding GENB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Savant Capital
Savant Capital Rockford, Illinois $35B AUM 15.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Barclays's GENB Position: Q3 2026 in Review

Barclays increased its Generate Biomedicines (GENB) stake by 1.3% in Q3 2026, buying an estimated $24.2K and bringing the position to 118,474 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2666.

Barclays first reported a position in GENB in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.97M in Q2 2026. 45 funds tracked by Wall St. Rank hold GENB as of Q3 2026.

  • Barclays held 118,474 shares of Generate Biomedicines worth $1.78M as of Q3 2026.
  • Barclays bought 1,572 Generate Biomedicines shares in Q3 2026, an estimated $24.2K.
  • Generate Biomedicines made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2666 holding.
  • Barclays first reported a position in Generate Biomedicines in Q1 2026 and has held it in 3 quarters since.
  • Barclays's Generate Biomedicines position peaked at $1.97M in Q2 2026.
  • 45 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.